Cite
MLA Citation
X Wu et al.. “998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095485662.0x000031